ProCE Banner Activity

Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Slideset

Downloadable slides with a comprehensive review of the optimal utilization of HER2-targeted treatment strategies for patients with advanced NSCLC from a live event.

Released: October 25, 2023

Share

Faculty

Lyudmila Bazhenova

Lyudmila Bazhenova, MD

Lung Cancer Unit Leader
Director 
Hematology and Oncology Training Program
University of California 
San Diego, California

Karen Reckamp

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Department of Medicine
Cedars-Sinai
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.